全球肌瘤切除术市场规模、份额和趋势分析报告 – 行业概况和 2031 年预测

肌瘤切除术市场分析

推动这一市场发展的因素包括育龄妇女中子宫肌瘤患病率的上升以及人们对微创手术选择的认识的提高。最近的发展包括机器人辅助手术技术的进步和腹腔镜器械的改进，这些技术提高了手术精准度、缩短了恢复时间并最大限度地减少了并发症。此外，超声和 MRI 等成像技术的创新有助于更好地诊断和制定治疗计划。患者对微创手术的倡导日益增多，对女性健康的关注也推动了肌瘤切除术市场的发展，从而导致对有效治疗选择的需求增加。总体而言，随着医疗保健提供者继续优先考虑以患者为中心的子宫肌瘤治疗方法，肌瘤切除术市场有望实现增长。

肌瘤切除术市场规模

2023 年全球肌瘤切除术市场规模价值 7.5852 亿美元，预计到 2031 年将达到 14.7517 亿美元，2024 年至 2031 年预测期内的复合年增长率为 8.67%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

肌瘤切除术市场趋势

“机器人辅助手术和腹腔镜方法的创新”

肌瘤切除术市场正在经历重大趋势，这得益于手术技术的进步和患者对微创手术的需求不断增长。机器人辅助手术和腹腔镜方法的创新正在改变子宫肌瘤的治疗方式，提供更高的精确度和更快的恢复时间。一个值得注意的趋势是门诊手术越来越受欢迎，患者可以接受肌瘤切除术并在同一天回家，最大限度地减少住院时间和相关费用。这种向门诊护理的转变反映了医疗保健行业在保持高护理标准的同时改善患者体验的更广泛趋势。随着对这些选择的认识不断提高，肌瘤切除术市场将扩大，强调有效且微创的子宫肌瘤治疗解决方案。

Report Scope and Myomectomy Market Segmentation         

Myomectomy Market Definition

Myomectomy is a surgical procedure performed to remove uterine fibroids (myomas) while preserving the uterus. It is typically recommended for women who wish to retain their fertility or avoid a hysterectomy. The procedure can be conducted through various approaches, including abdominal, laparoscopic, or hysteroscopic techniques, depending on the size, location, and number of fibroids. Myomectomy aims to alleviate symptoms associated with fibroids, such as heavy menstrual bleeding, pelvic pain, and pressure on surrounding organs, thereby improving the patient's quality of life.

Myomectomy Market Dynamics

Drivers

• Rising Prevalence of Uterine Fibroids

The rising prevalence of uterine fibroids among women of reproductive age serves as a significant market driver for myomectomy procedures. Fibroids are common benign tumors that can cause a range of symptoms, including heavy menstrual bleeding, pelvic pain, and pressure on surrounding organs. As awareness of these conditions increases, more women are seeking effective treatment options to alleviate their symptoms while preserving fertility. This growing demand for targeted interventions, such as myomectomy, is leading healthcare providers to prioritize these procedures, ultimately driving market growth. Addressing the needs of this patient population is crucial for enhancing quality of life and reproductive health.

•  Desire for Fertility Preservation

Many women choose myomectomy as a surgical option to remove uterine fibroids while preserving their uterus for potential future pregnancies. This desire for fertility preservation is a crucial factor influencing the demand for myomectomy procedures. Uterine fibroids can lead to complications during pregnancy and childbirth, prompting women to seek effective solutions that allow them to manage their symptoms without sacrificing their reproductive capabilities. As more women become aware of the benefits of myomectomy, including the ability to alleviate discomfort and retain fertility, healthcare providers are witnessing an increased interest in this procedure. This growing inclination significantly contributes to the expansion of the myomectomy market.

Opportunities

• Innovation in Minimally Invasive Surgical Techniques

Continuous innovation in minimally invasive surgical techniques, including robotic-assisted surgery and advanced laparoscopic methods, presents significant opportunities in the myomectomy market. These technologies enhance surgical precision, reduce recovery times, and minimize postoperative discomfort, making the procedures more appealing to patients. As patients increasingly prefer less invasive options that promote quicker healing and fewer complications, healthcare providers are motivated to adopt these innovative techniques. The development of user-friendly robotic systems and improved laparoscopic tools further supports this trend, potentially leading to better patient outcomes. By investing in these advancements, medical facilities can attract a larger patient population seeking effective and less invasive solutions for managing uterine fibroids.

• Increasing Public Awareness in Uterine Fibroids

Increasing public awareness about uterine fibroids and the various treatment options available can significantly drive demand for myomectomy procedures. Educational campaigns aimed at both patients and healthcare professionals are crucial in enhancing understanding of this common condition and its symptoms. By providing information on the potential complications of untreated fibroids and the benefits of timely intervention, these initiatives can encourage more women to seek diagnosis and consider myomectomy as a viable treatment option. Moreover, equipping healthcare providers with the latest knowledge on fibroid management can lead to earlier referrals and improved patient outcomes. This heightened awareness creates a fertile ground for growth in the myomectomy market.

Restraints/Challenges

• Competition from Alternative Treatments

The presence of alternative therapies, such as medication and less invasive procedures such as uterine artery embolization, poses a significant challenge to the myomectomy market. Many patients are increasingly inclined to explore these options due to their non-invasive nature and perceived lower risk profiles. Medications can offer symptom relief without the need for surgery, while uterine artery embolization provides a less invasive way to treat fibroids with shorter recovery times. This trend may lead to a decline in the number of women opting for myomectomy, as they may prioritize these alternative treatments over traditional surgical interventions. Consequently, healthcare providers must navigate this competitive landscape to promote myomectomy effectively.

• High Costs of Treatment

The financial burden associated with myomectomy can be a considerable restraint on its market growth, as the costs encompass various factors, including surgery fees, hospitalization, anesthesia, and postoperative care. For many patients, particularly those without comprehensive insurance coverage, these expenses can be overwhelming and may deter them from seeking necessary treatment. The high out-of-pocket costs may lead some women to delay surgery or opt for alternative treatments that are perceived as more affordable. This financial barrier restricts access to myomectomy, resulting in unmet medical needs and contributing to a lower rate of procedure adoption among eligible patients.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Myomectomy Market Scope

The market is segmented on the basis of type, product, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Robotic Myomectomy
• Abdominal Myomectomy
• Hysteroscopic Myomectomy
• Laparoscopic Myomectomy

Product

• Laparoscopic Power Morcellators
• Harmonic Scalpel
• Laparoscopic Sealer
• Others

End User

• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Medical Device Companies

Myomectomy Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, product, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

The North America region is at the forefront of the myomectomy market, driven by a growing patient population affected by uterine fibroids and robust medical reimbursement options. The accessibility of comprehensive healthcare coverage enables more women to seek myomectomy as an effective treatment choice. Additionally, advancements in surgical techniques and increased awareness of women's health issues further bolster the demand for myomectomy procedures in this region.

The Asia-Pacific region is poised for substantial growth in the myomectomy market from 2024 to 2031, driven by a rising number of women experiencing uterine fibroids. Increased awareness about the diagnosis and treatment options available for fibroids is fostering greater demand for surgical interventions. Additionally, the rapid modernization of healthcare infrastructure in many Asia-Pacific countries is enhancing access to advanced medical technologies and services, further supporting market expansion.

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。  

肌瘤切除术市场份额

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

在市场上运营的肌瘤切除术市场领导者是：

• 波士顿科学公司 (美国)
• CooperSurgical Inc.（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• Karl Storz SE（德国）
• Richard Wolf GmbH（德国）
• AbbVie Inc.（美国）
• 强生服务公司（美国）
• 美敦力（爱尔兰）
• 史赛克（美国）
• CONMED 公司 (美国)
• Hologic, Inc.（美国）
• B. Braun SE（德国）

肌瘤切除术市场的最新发展

• 2021 年 10 月，致力于开发针对症状性子宫肌瘤的微创解决方案的 Gynesonics 公司宣布，John Thoppil 博士成为德克萨斯州首位提供 Sonata 治疗的医生。目前，德克萨斯州奥斯汀 River Place 妇产科设施已为有症状的子宫肌瘤女性提供这种创新手术。通过提供这种办公室解决方案，Thoppil 博士旨在加强患者护理，并提供管理子宫肌瘤的有效替代方案
• 2021 年 9 月，专门为有症状的子宫肌瘤提供微创解决方案的 Gynesonics 公司宣布，美国食品药品监督管理局 (FDA) 批准了 Sonata® System 2.2。这款升级版系统为医疗机构、医生和患者带来了重大的新益处。此次批准彰显了 Gynesonics 致力于为患有子宫肌瘤的女性提供先进的治疗方案，提高护理的有效性和可及性
• 2021 年 10 月，Hologic, Inc. 收购了 Bolder Surgical，这是一家美国私营公司，以其尖端的能量血管封闭手术设备而闻名。此次收购不仅扩大了 Hologic 的手术产品组合，还增强了其在医疗保健市场的竞争地位。通过整合 Bolder Surgical 的创新技术，Hologic 旨在加强其产品组合并改善患者的手术效果
• 2021 年 8 月，全球领先的女性健康公司 Hologic, Inc. 宣布，美国第二大健康计划 Anthem Blue Cross Blue Shield 修改了其医疗政策，将射频消融 (LAP-RFA) 纳入保险范围。此次更新特别涵盖了针对子宫肌瘤女性的 Acessa 手术（CPT 代码 58674）。扩大保险范围的决定反映了人们越来越认识到需要针对这种常见疾病的有效治疗方案，最终改善受影响患者的医疗服务
• 2020 年 8 月，Hologic Inc. 完成了对 Acessa Health Inc. 的收购，Acessa Health Inc. 是一家私营公司，以专注于子宫肌瘤的微创治疗而闻名。此次战略收购增强了 Hologic 在子宫肌瘤治疗市场的产品供应，使其能够提供更广泛的创新解决方案。通过整合 Acessa Health 的专业知识和技术，Hologic 旨在增强患者护理并改善子宫肌瘤女性的治疗效果

SKU-63640